US Dollar vs Yen

登録してリアルタイムのアラート、カスタムポートフォリオ、市場の動きを入手してください。

ホーム
投資
株式
イギリス
LSE
Celon Pharma SA (0RKX) 銘柄情報

Celon Pharma SA (0RKX)

29.00

0.00

(0.00%)

終了 7月11日 12:30AM

Celon Pharma SA (0RKX) 銘柄情報

リアルタイムのストリーミング引用、アイデア、ライブディスカッションのハブ

プレミアム

通貨

29.00

( - )

買値

29.00

売値

29.00

出来高

0.00

平均取引量 (3 か月)

PLN 8,773

財務取引量

-

0.00 日の範囲 0.00

29.00 52 週間の範囲 29.00

時価総額

企業価値

1.11B

前日終値

29.00

始値

-

時刻

最終取引時間

VWAP

-

歳入

256.54M

純利益

108.32M

発行済株式数

53,856,500

浮動株比率 (%)

44.23%

機関投資家保有比率 (%)

17.98%

配当利回り

PER

9.74

株価売上高倍率 (PSR)

4.15

1 株当たり利益 (EPS)

2.03

ベータ

0.67

Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is base... Celon Pharma S.A., an integrated pharmaceutical company, engages in the research, manufacture, and marketing of specialised generic products. The company provides drugs to treat cancers, neurological diseases, diabetes, and other metabolic disorders. Celon Pharma S.A. was founded in 2002 and is based in Lomianki, Poland. The company operates as a subsidiary of Glatton Sp. z o.o. 詳細を表示

セクター

Health Care

業界

-

ウェブサイト

www.celonpharma.com

本社

Lomianki, Poland

設立

2026

Celon Pharma SA is listed in the Health Care sector of the ロンドン証券取引所 with ticker 0RKX. The last closing price for Celon Pharma was PLN29. Over the last year, Celon Pharma shares have traded in a share price range of PLN 29.00 to PLN 29.00.

Celon Pharma currently has 53,856,500 shares in issue. The market capitalisation of Celon Pharma is PLN1.56 billion. Celon Pharma has a price to earnings ratio (PE ratio) of 9.74.

表示するニュースはありません。

期間 †	前日比	前日比 %	始値	高値	安値	平均出来高	VWAP
1	0	0	0	0	0	0	0	DE
4	0	0	0	0	0	0	0	DE
12	0	0	0	0	0	0	0	DE
26	0	0	29	29	29	0	0	DE
52	0	0	29	29	29	0	0	DE
156	0	0	29	29	29	2056	29	DE
260	0	0	29	29	29	1182	29	DE

0RKX - Frequently Asked Questions (FAQ)

What is the current Celon Pharma SA share price?

The current share price of Celon Pharma SA is PLN 29.00

How many Celon Pharma SA shares are in issue?

Celon Pharma SA has 53,856,500 shares in issue

What is the market cap of Celon Pharma SA?

The market capitalisation of Celon Pharma SA is PLN 1.56B

What is the 1 year trading range for Celon Pharma SA share price?

Celon Pharma SA has traded in the range of PLN 29.00 to PLN 29.00 during the past year

What is the PE ratio of Celon Pharma SA?

The price to earnings ratio of Celon Pharma SA is 9.74

What is the cash to sales ratio of Celon Pharma SA?

The cash to sales ratio of Celon Pharma SA is 4.15

What is the registered address of Celon Pharma SA?

The registered address for Celon Pharma SA is Ogrodowa 2A, Lomianki, 05-092

What is the Celon Pharma SA website address?

The website address for Celon Pharma SA is www.celonpharma.com

mascale

mascale 3分前

Recent Hiru-OTC news indicates stabilizing year-end.

urge2surge

urge2surge 4分前

Share update. Waiting on schwab data.
https://www.otcmarkets.com/stock/FDCTD/security

misterfishman

misterfishman 9分前

Well if its a future reality thens its not happening in this reality and no i dont do mushrooms or any type of drugs lol. Dreams happen all the time i guess when you want a thing so badly that sometimes you dream about it.wishing for a thing doesnt make it so.

SmallCaps55

SmallCaps55 10分前

Seems pretty simple to me. Would the company try to flip that and state that the R value only applies to convection heat and not infrared heat? hot plates typically do not emit that much radiation heat, mainly just convectively heating the air.

There is a very simple way that the Ric

CryptoRain

CryptoRain 16分前

Keep going…the only bad thing is you’re going to make undeserved rewards here and look amazingly bad in the process

Golden Cross

Golden Cross 22分前

$HIRU AMEEREX CORPORATION ENGAGES PCAOB-REGISTERED AUDITOR VM CPA FIRM TO AUDIT 2024 AND 2025 FINANCIAL STATEMENTS
https://www.otcmarkets.com/stock/HIRU/news/AMEEREX-CORPORATION-ENGAGES-------PCAOB-REGISTERED-AUDITOR-VM-CPA-FIRM-TO-AUDIT-2024-AND-2025-FINANCIAL-------STATEMENTS?id=527509

Doc logic

Doc logic 22分前

Nemesis18,

No, what it smacks of is validation of the exceptions pathway to adequate and well controlled studies which is something mentioned on this board back in 2016. This is near the final prep for filing a BLA with FDA and other regulators after MHRA approval. This also buys ti

Golden Cross

Golden Cross 28分前

You are correct rheddle...

berigud

berigud 28分前

Damn, no need for a super expensive, special build, testing machine when a light bulb and cardboard box shows it all.

We have been had.

FormalMHRAconsultant

FormalMHRAconsultant 33分前

So no, I am certain there was a formal rejection=So no, I am certain there was NOT a formal rejection

JRyan

Same Formation Different Rock: The Megiddo-Jezreel Deliverability Question

https://i.postimg.cc/P5kxbr1W/rig-header-clean.jpg
(Illustrative image — AI-generated. Not a photograph of the JB-1 rig or the MJ-02 site.)

What the Meged field tells us — and doesn't — ab

stock king 1

stock king 1 37分前

Look what he did with hemp and Gtvh he will do the same with Vxit .. he will run it to over 20 billion shares …. You will be left with a bag of chit

arachnodude

arachnodude 39分前

Crazy how every discussion eventually drifts away from KBLB's progress and toward confidently assigning motives, intentions, and personality traits to the CEO. One might almost forget the investment thesis is supposed to be recombinant spider silk and not speculative psychoanalysis of the company's

stock king 1

stock king 1 39分前

You buy this scam you will get screwed big time

Seminole Red

Seminole Red 40分前

round 3 will resume at 8:10....EST

Monksdream

Monksdream 41分前

NVDA, still rebounding off the 200 sma
https://investorshub.advfn.com/uimage/uploads/2026/7/11/rjkutIMG_2278.png

erg61

According to Northwest Biotherapeutics’ public statements and filings, the company has not said that it would never apply to the FDA, nor has it stated that it chose not to pursue U.S. approval permanently. Rather, management’s stated position has been that they decided to prioritize the UK and othe

Frank69OH

Frank69OH 43分前

Financials should be able to give some insight.

Curt D

Curt D 49分前

Yep. $150 support is no more.

seventhcircle

seventhcircle 50分前

$TKOI nice dip Friday looks like it got soaked up

Monksdream

Monksdream 50分前

IVES, trending sideways
https://investorshub.advfn.com/uimage/uploads/2026/7/11/crnsmIMG_2276.png

seventhcircle

seventhcircle 52分前

$NICH holding 001 support https://x.com/nitchescorp/status/2075197041609789881?s=46

moczowy

moczowy 53分前

Check out @GuruChartist message on Stocktwits http://stocktwits.com/George/message/658776713

toohot

toohot 57分前

Pallet of 1,200 PAINKILLER™ ActiPatch® Pulsed Short Wave Therapy (PSWT) devices. Maximum wholesale tier with the deepest per-unit discount, 10% lower than the case pack rate. FDA-cleared, 30-day battery, waterproof.
Shipping information
We process and deliver orders Monday-Friday (excl

Mitsu Hc Cap 24

Virgin Wines UK

Hsbc Usa Inc Autocallabl...

Ci North American Smallm...

Sunrise Energy Metals (QX)

Grupul Industrial Electr...

Delayed Upgrade Clock

顧客サポート: +44 (0) 203 8794 460 | support@advfn.com

ADVFNのサービスをご利用いただくには、利用規約

ADVFN

すでにアカウントをお持ちですか？サインイン

アカウントをお持ちでないですか？登録

登録することで、ADVFN の利用規約を読み、理解し、同意したこと、および私が個人投資家であることを確認します。